CTRI/2020/09/027619尚未招募1 期
A randomized, double-blind, three-arm, balanced, single-dose, parallel-groupstudy comparing pharmacokinetics and pharmacodynamics of Intas Denosumab(120 mg/1.7 mL) of Intas Pharmaceuticals Limited, India with Xgeva® of AmgenInc., USA and Xgeva of Amgen Europe B.V., The Netherlands in normal, healthy,adult human male subjects
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Normal, healthy, adult, human male subjects greater than equal to 28 to less than equal to 55 years of age (both inclusive)
- •2. Having a Body Mass Index (BMI) between 18.5 to 30 (both inclusive) kg / m2 and
- •weighing > 50 kg and less than 90 kg.
- •3. Able to comply with the study procedures, as per the opinion of the Principal Investigator.
- •4. Able to give voluntary written informed consent for participation in the trial.
- •5. Not having any significant disease or abnormal findings during screening, medical
- •history, clinical examination, vital sign examination (Pulse rate, blood pressure,
- •Respiratory rate and temperature), laboratory evaluations, 12- lead ECG and X-ray chest
- •(P/A view).
排除标准
- •1.History of hypersensitivity or idiosyncratic reaction to Denosumab or its excipients or prior use of denosumab or other Chinese Hamster Ovary cell line derived products or to drugs of similar chemical classes or any related drug.
- •2.Subjects with known latex allergies.
- •3.Subjects will be assessed for postural hypotension (Defined as decrease in systolic blood pressure of 20 mm Hg or a decrease in diastolic blood pressure of 10 mm Hg and increase in heart rate (greater than 20 bpm) (compared to the sitting results) within 3 minutes of standing when compared with blood pressure from sitting position) and confirmed unsafe for study inclusion by the investigator.
- •4.History or presence of any disease or disorder known to influence bone metabolism including history of non-traumatic fractures except Vitamin D deficiency requiring replacement.
- •5.History or presence of any disease or disorder known to compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
- •6.Any clinically significant ECG abnormalities at Screening.
- •7.Any evidence of tuberculosis as per X-ray chest (P/A view) recordings.
- •8.History of malignancy of any organ system treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
- •9.Fertile males, defined as all males physiologically capable of conceiving offspring UNLESS the subject agrees to comply with two highly effective contraceptive methods comprising a barrier method (condom or occlusive cap plus spermicide) for the entire duration of the study, up to end of the study (after last ambulatory sample),.
- •10.Smokers or tobacco users, who consumed tobacco or tobacco-containing products (gutkha, pan/pan masala, beedi, cigarettes, others) within 6 months prior to start of the study or has inability to abstain from smoking during the study period.
- •11.Subjects with history of ingestion of any prescription drugs, herbal supplements within 4 weeks prior to initial dosing and/or over-the-counter (OTC) medication, dietary supplements (vitamins included except vitamin D supplements provided during the study and prescreening) within 2 weeks prior to dosing. In any such case, subject selection will be at the discretion of the Principal Investigator.
- •12.Consumption of grapefruit or grapefruit products within 72 hours prior to dosing.
- •13.Donation of blood (1 unit or 350 mL) or receipt of an investigational drug or product or participation in a drug research study within 6 months prior to receiving the dose of the study medicine.
- •14.A history of difficulty with donating blood.
- •15.Significant illness within two (2) weeks prior to dosing.
- •16.Recent (within the last three [3] years) and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting, palpitations, etc).
- •17.Recent (within the last three [3] years) and/or recurrent history of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).
- •18.History of any food allergies.
- •19.Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study.
研究者
相似试验
尚未招募
Unknown
This is a randomized, double-blind, three-arm, balanced, single-dose, parallel-group, Clinical Study to Compare the Pharmacokinetics, Safety, & Immunogenicity of pertuzumab biosimilar vs. Perjeta® (US & EU sourced) in normal, healthy, adult, human male subjects.CTRI/2023/06/054131Intas Pharmaceuticals Ltd Biopharma Division
进行中（未招募）
Unknown
A clinical study to check the safety and effectiveness of test treatments in adult human subjects having anemia or iron-deficiency anemiaCTRI/2023/10/059283ORGENETICS INC
进行中（未招募）
1 期
Parallel group, blinded, multi-centre study of mifepristone in patients with endometriosisendometriosis in reproductive-ageMedDRA version: 20.0 Level: PT Classification code 10014778 Term: Endometriosis System Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2018-002367-26-HUitaphar Laboratorios490
进行中（未招募）
1 期
Parallel group, blinded, multi-centre study of mifepristone in patients with endometriosisendometriosis in reproductive-ageMedDRA version: 20.0Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2018-002367-26-BGitaphar Laboratorios220
进行中（未招募）
1 期
Parallel group, blinded, multi-centre study of mifepristone in patients with endometriosisEUCTR2018-002367-26-PLitaphar Laboratorios490